Comparison of the efficacy of decitabine combined with micro-transplantation or priming regimen as consolidation treatment for older patients with acute myeloid leukemia.
10.3760/cma.j.issn.0253-2727.2018.04.010
- VernacularTitle:地西他滨联合微移植巩固治疗首次完全缓解老年急性髓系白血病的疗效与安全性分析
- Author:
Wei Yang LI
1
;
Yu Feng FENG
;
Xiao MA
;
Hui Ying QIU
;
Cheng Cheng FU
;
Xiao Wen TANG
;
Yue HAN
;
De Pei WU
;
Ai Ning SUN
Author Information
1. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, China.
- Publication Type:Journal Article
- Keywords:
Aged;
Decitabine;
Leukemia, myeloid, acute;
Micro-transplantation
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Consolidation Chemotherapy;
Cytarabine;
Decitabine/administration & dosage*;
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Middle Aged;
Treatment Outcome
- From:
Chinese Journal of Hematology
2018;39(4):305-309
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To probe the feasibility of decitabine (DAC) combined with micro-transplantation as consolidation treatment for older patients with acute myeloid leukemia (AML). Methods: Between November 2012 and September 2015, 37 consecutive patients with AML ≥60 years of age were analyzed. Of them, 19 patients received consolidation therapy with DAC followed by micro-transplantation (microtransplant group). Another 18 ones (chemo group) were treated with DAC plus priming regimen as consolidation chemotherapy in the same period. Results: There were no significant differences in terms of age, WBC count, and disease status of onset between the microtransplant and chemo groups (P>0.05). The two regimens were well tolerated. There was no difference of CTC grade 3-4 nonhematologic toxicities between the microtransplant and chemo groups (36.8% vs 27.8%, χ(2)=0.347, P=0.728). The median recovery durations for neutrophil and platelet in the microtransplant group were similar to those in the chemo group (12 vs 13 days, z=1.599, P=0.110; 14 vs 12 days, z=-1.314, P=0.189, respectively). No graft-versus-host disease was observed in the microtransplant group. The 2-year leukemia-free survival and overall survival were better in microtransplant group (50.7% and 54.9%, respectively) than in chemo group (24.3% and 30.0%, respectively) (P=0.047 and P=0.071, respectively). Conclusion: DAC combined with micro-transplantation as a consolidation regimen may be a safe and promising option for older patients with AML.
